ArticleNeuroinformatics2026
Corpus Callosum Segmentation on Structural MRI Using Multi-atlas Deformable Registration.
Article in Neuroinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The corpus callosum (CC), the largest white matter structure in the brain, exhibits morphological changes in normal aging and neurodegenerative disorders. A reliable CC segmentation method facilitates early detection and monitoring of neurological disorders such as Alzheimer’s disease (AD). This study presents Yuki, a fully automated CC segmentation program, evaluates its performance, and demonstrates its utility in structural MRI analysis. We describe an automated method for CC segmentation on structural MRI using multi-atlas deformable registration. Accuracy is assessed in 90 participants using the Dice Similarity Coefficient (DSC). Cross-sectionally, 100 cognitively normal (CN) and 100 AD participants are compared in CC area, circularity, and thickness. Longitudinally, test-retest reliability is evaluated in 49 participants with back-to-back scans, and CC circularity decline is analyzed over two years in 62 CN and 55 AD participants. Yuki achieved a DSC of 97.4% on the test set and 98.2% in the test-retest analysis. Cross-sectionally, CC area, circularity, and thickness were significantly reduced in AD compared to CN (p < .001, p < .0001, p < 10⁻6). Point-wise analysis showed diffuse CC thinning in AD except at the isthmus. CC circularity declined significantly over two years in both CN and AD, with a faster rate in AD (p < 10⁻15, p < 10⁻15, p < 10⁻4). Yuki provides accurate, reliable, and reproducible CC segmentation for 3D MRI. Its application in AD highlights its utility in neurodegenerative research, where declines in CC thickness and circularity can serve as structural biomarkers of interest.
Indexed as
Identifiers
42029989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.